

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM473311

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Xoma (US) LLC		05/07/2018	Limited Liability Company: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Silicon Valley Bank		
<b>Street Address:</b>	505 Howard Street, 3rd Floor		
<b>City:</b>	San Francisco		
<b>State/Country:</b>	CALIFORNIA		
<b>Postal Code:</b>	94105		
<b>Entity Type:</b>	Corporation: CALIFORNIA		
<b>PROPERTY NUMBERS Total: 6</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	3791541	XOMA	
<b>Registration Number:</b>	4162526	XOMA	
<b>Serial Number:</b>	87765499	XOMA	
<b>Serial Number:</b>	87765493	XOMA	
<b>Registration Number:</b>	4514731		
<b>Registration Number:</b>	4042397	XOMA	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	8004947512		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	202-370-4750		
<b>Email:</b>	ipteam@cogencyglobal.com		
<b>Correspondent Name:</b>	Joanna McCall		
<b>Address Line 1:</b>	1025 Vermont Ave NW, Suite 1130		
<b>Address Line 2:</b>	COGENCY GLOBAL INC.		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>ATTORNEY DOCKET NUMBER:</b>	F176914		
<b>NAME OF SUBMITTER:</b>	Laura A. Kenerson		
<b>SIGNATURE:</b>	/Laura A. Kenerson/		

OP \$165.00 3791541

**DATE SIGNED:**

05/08/2018

**Total Attachments: 17**

source=USPTO Submission - Xoma (US) LLC (Trademarks)#page2.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page3.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page4.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page5.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page6.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page7.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page8.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page9.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page10.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page11.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page12.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page13.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page14.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page15.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page16.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page17.tif  
source=USPTO Submission - Xoma (US) LLC (Trademarks)#page18.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement (this "Agreement") is entered into as of May 7, 2018, by and between SILICON VALLEY BANK, a California corporation, with a loan production office located at 505 Howard Street, 3<sup>rd</sup> Floor, San Francisco, California 94105 ("Bank") and XOMA (US) LLC, a Delaware limited liability company with its principal place of business located at 2200 Powell Street, Suite 310, Emeryville, California 94608 ("Grantor").

### RECITALS

A. Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Grantor, XOMA CORPORATION, and XOMA TECHNOLOGY LTD., dated as of the date hereof (as the same may be amended, restated, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor to Bank.

B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Grantor's obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

### AGREEMENT

1. Grant of Security Interest. To secure Grantor's obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property (all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those registered or filed with the United States Copyright Office and set forth on Exhibit A attached hereto (collectively, the "Copyrights");

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications registered or filed with the United States Patent and Trademark Office and set forth on Exhibit B attached hereto (collectively, the "Patents");

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the "Trademarks");

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those registered or filed with the United States Patent and Trademark Office and set forth on Exhibit D attached hereto (collectively, the "Mask Works");

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

2. Recordation. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials to record and register this Agreement upon request by Bank.

3. Loan Documents. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual

Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.

4. Execution in Counterparts. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.

5. Successors and Assigns. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.


6. Governing Law. This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of California, without giving effect to any choice or conflict of law provision or rule (whether of the State of California or any other jurisdiction).

[Signature page follows.]

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

XOMA (US) LLC

By: 

Title: Chief Financial Officer

BANK:

SILICON VALLEY BANK

By: \_\_\_\_\_

Title: \_\_\_\_\_

IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

XOMA (US) LLC

By: \_\_\_\_\_

Title: \_\_\_\_\_

BANK:

SILICON VALLEY BANK

By: *Paul S. [Signature]*

Title: *Vice President*

EXHIBIT A

Copyrights

None.





2.		Title:	METHODS FOR TREATMENT OF IL-1BETA RELATED DISEASES
		Inventors:	Alan M. Solinger; Patrick J. Scannon; Robert J. Bauer; David Alleva
		Assignee:	XOMA (US) LLC
(Gevo Fam 2 T2D)			

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	60/871,046	12/20/06		
US Provisional	60/908,389	03/27/07		
US Provisional	60/911,033	04/10/07		
PCT	PCT/US07/088411	12/20/07	WO 08/077145	
US	11/961,764	12/20/07	7,695,718 B2	12/20/2027
US Con	12/710,842	02/23/10	8,101,166 B2	12/20/2027
US Con 2	12/757,885	04/09/10	8,586,036 B2	12/20/2027
US Con 3	14/042,205	09/30/13	9,163,082 B2	12/20/2027

3.		Title:	METHODS FOR TREATMENT OF GOUT
		Inventor:	Alan M. Solinger
		Assignee:	XOMA (US) LLC
(Gevo Fam 3 Gout)			

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/015,633	12/20/07		
US Provisional	61/059,378	06/06/08		
US Provisional	61/095,191	09/08/08		
PCT	PCT/US08/087519	12/18/08	WO 2009/086003	
US	12/338,957	12/18/08	8,637,029 B2	12/18/2028

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Con 2	15/419,991	01/09/17	2017/0355764 A1	12/18/2028
4.				
Title:	METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS			
Inventors:	Alan M. Solinger; Alexander Owyang			
Assignee:	XOMA (US) LLC			
(Geva Fam 4 RA)				

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/059,711	06/05/08		
US Provisional	61/095,232	09/08/08		
PCT	PCT/US09/46441	06/05/09	WO 2009/149370	

5.				
Title:	METHODS FOR TREATING OR PREVENTING IL-1BETA RELATED DISEASES			
Inventors:	Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer			
Assignee:	XOMA (US) LLC			

(Geva Fam 5 ULID)				
COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/094,842	09/05/08		
US Provisional	61/121,451	12/10/08		
PCT	PCT/US09/56086	09/04/09	WO 2010/028275	
US	13/062,457	09/04/09	8,545,846 B1	09/04/2029

6.				
Title:	METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION			
Inventors:	Patrick J. Scannon, Alan M. Solinger, Robert J. Bauer			

Assignee: XOMA (US) LLC  
 (Gevv Fam 6 BC)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/094,857	09/05/08		
US Provisional	61/121,486	12/10/08		
PCT	PCT/US09/56084	09/04/09	WO 2010/028273	
US	13/062,461	09/04/09	8,377,429 B2	09/04/2029

7. Title: CARDIOVASCULAR RELATED USES OF IL-1B ANTIBODIES AND BINDING FRAGMENT'S THEREOF  
 Inventors: Patrick J. Scannon, Alan M. Solinger, Jeffrey D. Feldstein  
 Assignee: XOMA (US) LLC  
 (Gevv Fam 7 CV)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/182,679	05/29/09		
US Provisional	61/252,571	10/16/09		
US Provisional	61/313,001	03/11/10		
PCT	PCT/US10/36761	05/28/10	WO 2010/138939	
US	15/647,203 (Con)	07/11/17		05/28/2030

8. Title: METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS  
 Inventors: Alan M. Solinger, Ahmet Gill  
 Assignee: XOMA (US) LLC  
 (Gevv Fam 8 U-B)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST. EXP

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/332,658	05/07/10		
US Provisional	61/334,125	05/12/10		
US Provisional	61/444,638	02/18/11		
PCT	PCT/US11/35646	05/06/11	WO 2011/140522	
US	13/102,768	05/06/11	8,551,487 B1	05/06/2031
US Con	14/029,603	09/17/13	9,139,646 B2	05/06/2031

9.				
Title:	METHODS FOR TREATING ACNE			
Inventors:	Paul Rubin			
Assignee:	XOMA (US) LLC			
(Gevo Farm 9 Acne)				

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/577,450	12/19/11		
PCT	PCT/US12/70734	12/19/12	WO2013096516 A1	

10.				
Title:	FLEXIBLE MANUFACTURING SYSTEM			
Inventors:	Patrick J. Scannon, Frank Bernard, Alfred C. Dadson, Jr., and Robert Tenerowicz			
Assignee:	XOMA (US) LLC			
(FMS)				

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP
US Provisional	61/140,339	12/23/08		
US Provisional	61/227,658	07/22/09		
PCT	PCT/US09/69204	12/22/09	WO 2010/75389	
US	13/129,073	12/22/09	2011-0258837 A1	12/22/2029
US Con	13/677,832	11/15/12	8,584,349 B2	12/22/2029

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	
US Con 2	15/349,298	11/11/16	20170058508	12/22/2029	
11. Title: INSULIN RECEPTOR BINDING ANTIBODIES					
Inventor: John Corbin, Mark Leslie White, Susan R. Watson and Vinay Bhaskar					
Assignee: XOMA (US) LLC					
(XMet)					

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	Notes re Claims
US Provisional	61/246,067	09/25/09			
US Provisional	61/306,321	02/19/10			
US Provisional	61/358,749	06/25/10			
PCT	PCT/US10/50313	09/25/10	WO2011/038302		
US	12/890,598	09/24/10	8,926,976 B2	02/19/2032	XMetA claims
US	14/555,233	11/26/14	2016-0009800-A1	09/24/2030	XMetD claims
US	14/555,243	11/26/14	9,725,510 B2	08/23/2031	XMetA seq claims

12. Title: TREATMENT OF POST-PRANDIAL HYPERINSULINEMIA AND HYPOGLYCEMIA AFTER SURGERY					
Inventors: Paul Rubin, Rajneesh Prem, Kirk W. Johnson					
Assignee: XOMA (US) LLC					
(X358 XMetD-PPH)					

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	Notes re Claims
US Prov	62/127,788	03/03/15		03/03/2016	
US Prov 2	62/288,955	01/29/16		01/29/2017	
PCT	PCT/US2016/020539	03/03/16	WO 2016/14111	03/03/2036	
US	15/555,608	03/03/16	US2018-0037658-A1	03/03/2036	

EPO 16711070.9 03/03/16 3265491 A1 03/03/2036

13 Title: ANTIBODY FRAGMENTS AGAINST THE INSULIN RECEPTOR AND USES THEREOF TO TREAT HYPOGLYCEMIA

Inventors: Paul Rubin, Toshitiko Takeuchi, Hassan Issaifas, Kiranjit Ahluwalia, Ira Goldfine and John Corbin, Kirk W. Johnson; Ou Li; Daniel H. Bedinger

Assignee: XOMA (US) LLC  
(X129 XMelD-Fab)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	Notes re Claims
US Prov	62/202,143	08/06/15			
US Prov 2	62/280,675	01/19/15			
PCT	PCT/US2016/045917	08/05/16	WO/2017/024285 A2		
US	15/230,340	08/05/16	US2017-0037135 A1	08/05/2036	
US Con	15/897,852	02/15/18		08/05/2036	

14 Title: PARATHYROID HORMONE RECEPTOR 1 (PTH1R) ANTIBODIES AND USES THEREOF

Inventors: Raphael David Levy, Hassan Issaifas, Kirk W. Johnson, Agnes Choppin Holmes, Amer M. Mirza, Daniel H. Bedinger, Toshitiko Takeuchi, Rachel A. Hunt, Robyn Cotter, Kiranjit Kaur Ahluwalia

Assignee: XOMA (US) LLC  
(PTH1R)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	Notes re Claims
US Prov	62/369,745	01-Aug-2016		08/01/2017	
US Prov 2	62/432,338	09 Dec 2016		12/09/2017	
US Prov 3	62/479,637	03/31/2017		03/31/2018	

PCT	PCT/US2017/044789	08/01/2017	WO/2018/026748 A1	08/01/2037	
US	15/665,788	08/01/2017	20180030154 A1	08/01/2037	

15. Title: ANTIBODIES THAT BIND INTERLEUKIN-2 AND USES THEREOF

Inventors: Marina Roell, Mark Rubenstein, Hassan Issafras, Llewelyn Lao, Ou Li, Daniel Bedinger, Kristen Lind, Agnes Choppin-Holmes, Toshitiko Takeuchi, Lauren Schwimmer, Hoa Giang, Amer H. Mirza; Kirk Johnson

Assignee: XOMA (US) LLC  
(IL2 MUSC)

COUNTRY	APPLICATION	FILE DATE	PATENT/PUBLICATION	EST EXP	Notes re Claims
US Prov	62/401,158	28-Sep-2016		09/28/17	
US Prov 2	62/421,038	11-Nov-2016		11/11/17	
PCT	PCT/US2017/053880	09/28/17		09/28/37	
US	15/718,152	09/28/17		09/28/37	



<u>Patent</u>	<u>Patent No./Application No</u>	<u>Patent Date</u>	<u>Owner</u>
CONJUGATED ANTI-CD38 ANTIBODIES	14754592	Jun 29, 2015	Xoma (US), LLC
CONJUGATED ANTI-CD38 ANTIBODIES	13977207	Feb 13, 2014	Xoma (US), LLC
METHODS FOR TREATING ACNE	14366664	Jun 18, 2014	Xoma (US), LLC
ANTI-CD38 ANTIBODIES	14550796	Nov 21, 2014	Xoma (US), LLC
ANTI-CD38 ANTIBODIES	13720837	Dec 19, 2012	Xoma (US), LLC
CARDIOVASCULAR RELATED USES OF IL-1BETA ANTIBODIES AND BINDING FRAGMENTS THEREOF	12790738	May 28, 2010	Xoma (US), LLC
METHODS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS	12996516	Mar 22, 2011	Xoma (US), LLC
METHODS FOR IMPROVEMENT OF BETA CELL FUNCTION	13739715	Jan 11, 2013	Xoma (US), LLC
METHODS FOR THE TREATMENT OF GOUT	14137892	Dec 20, 2013	Xoma (US), LLC
ANTI-CD38 ANTIBODIES	13341860	Dec 30, 2011	Xoma (US), LLC
CONJUGATED ANTI-CD38 ANTIBODIES	13977207	Feb 13, 2014	Xoma (US), LLC
METHODS FOR THE TREATMENT OF IL-1BETA RELATED CONDITIONS	13102768	May 6, 2011	Xoma (US), LLC
NUCLEIC ACID MOLECULES FOR OPTIMIZED CAB-2 EXPRESSION AND THEIR USE	11302782	Dec 14, 2005	Xoma (US), LLC
THERAPEUTIC PEPTIDE-BASED CONSTRUCTS DERIVED FROM DOMAIN II OF BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN	09344219	Jun 25, 1999	Xoma (US), LLC
DERIVATIVE COMPOUNDS DERIVED FROM OR BASED ON BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN	09344541	Jun 25, 1999	Xoma (US), LLC
ANTIFUNGAL COMPOUND	09975638	Oct 11, 2001	Xoma (US), LLC
THERAPEUTIC USES OF BPI PROTEIN PRODUCTS IN HUMANS WITH OTITIS MEDIA WITH EFFUSION	09586850	Jun 5, 2000	Xoma (US), LLC

EXHIBIT C

Trademarks


Country	Title	App. No.	App. Date	Reg. No.	Reg. Date
United States of America	XOMA	77/979281	5/28/2008	3791541	5/18/2010
United States of America	XOMA	85/976777	11/1/2010	4162526	6/19/2012
United States of America	XOMA	87/765499	1/22/2018		
United States of America		87/765493	1/22/2018		
United States of America		86/077245	9/27/2013	4514731	4/15/2014
United States of America	XOMA	77/485239	5/28/2008	4042397	10/18/2011

EXHIBIT D

Mask Works

None.